Intratumoral injection of cGAMP20,21, or systemic administration of metabolically stable synthetic STING agonists22–24, has been shown to inhibit tumor growth in a variety of syngeneic mouse tumor models by promoting STING/IRF3 signaling18–20,25,26. This evidence concerns the gene IRF3 and neoplasm.